Top Markets
#1 Siren Siren +39.12%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#3 Ocean Protocol Ocean Protocol +15.51%
#4 KUB Coin KUB Coin +15.08%
#5 Perle Perle +11.39%
#6 Audiera Audiera +11.03%
#7 Nockchain Nockchain +9.99%
#8 Geodnet Geodnet +9.30%
#9 Arowana Arowana +8.26%
#10 Wiki Cat Wiki Cat +8.24%
Coin of the day
Siren Siren
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.

VTGN
Classement en actions #31934
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Prix de l'action
$0.2619
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$11.62M
Changement (1 jour)
-2.13%
Changement (1 an)
-92.30%
Pays
US
Échange VistaGen Therapeutics, Inc. (VTGN)

Catégorie

Healthcare
Le prix VTGN avec la capitalisation boursière de B
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
VTGN
$0.2619
Capitalisation boursière de VistaGen Therapeutics, Inc.(VTGN)
Capitalisation boursière: $11.62M
En August 2026, VistaGen Therapeutics, Inc. a une capitalisation boursière de $11.62M. Cela fait de VistaGen Therapeutics, Inc. la 31934th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de VistaGen Therapeutics, Inc. du 2011 au 2026
VTGN par rapport au top 5 des plus populaires stocks
Prix pour VTGN L’actif B La capitalisation boursière de B Résultats
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$123,040 $11.62M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.460T +46,979,716.61%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$101,167 $11.62M
Apple Inc. Apple Inc.
AAPL
$4.489T +38,628,057.12%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$93,311.87 $11.62M
Alphabet Inc. Alphabet Inc.
GOOG
$4.141T +35,628,715.01%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$80,414.22 $11.62M
Microsoft Corporation Microsoft Corporation
MSFT
$3.569T +30,704,070.07%
VistaGen Therapeutics, Inc. VistaGen Therapeutics, Inc.
$63,051.48 $11.62M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.798T +24,074,540.22%